Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events

Background and aims: Current guidelines state that infliximab is contraindicated for the treatment of immune checkpoint inhibitor-related hepatitis (ir-hepatitis) due to the risk of inducing further liver damage. As this recommendation is largely based on the use of infliximab for rheumatologic dise...

Full description

Bibliographic Details
Main Authors: Daniel V. Araujo, Thiago Pimentel Muniz, Anjie Yang, Sareh Keshavarzi, Hadas Sorotsky, Marcus O. Butler, Samuel Saibil, Anna Spreafico, David Hogg
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Current Oncology
Subjects:
infliximab
immunotherapy
toxicity
hepatotoxicity
immune-checkpoint inhibitors
Online Access:https://www.mdpi.com/1718-7729/28/3/201

Internet

https://www.mdpi.com/1718-7729/28/3/201

Similar Items